These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

419 related items for PubMed ID: 11076649

  • 1. Undetectable ultrasensitive PSA after radical prostatectomy for prostate cancer predicts relapse-free survival.
    Doherty AP, Bower M, Smith GL, Miano R, Mannion EM, Mitchell H, Christmas TJ.
    Br J Cancer; 2000 Dec; 83(11):1432-6. PubMed ID: 11076649
    [Abstract] [Full Text] [Related]

  • 2. Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy.
    Shen S, Lepor H, Yaffee R, Taneja SS.
    J Urol; 2005 Mar; 173(3):777-80. PubMed ID: 15711268
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Postoperative prostate-specific antigen velocity independently predicts for failure of salvage radiotherapy after prostatectomy.
    King CR, Presti JC, Brooks JD, Gill H, Spiotto MT.
    Int J Radiat Oncol Biol Phys; 2008 Apr 01; 70(5):1472-7. PubMed ID: 17935902
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Prognostic significance of undetectable ultrasensitive prostate-specific antigen nadir after radical prostatectomy.
    Hong SK, Park HZ, Lee WK, Kim DS, Lee JS, Doo SH, Jeong SJ, Yoon CY, Byun SS, Lee SE.
    Urology; 2010 Sep 01; 76(3):723-7. PubMed ID: 20579699
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
    Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC.
    J Urol; 2003 Feb 01; 169(2):517-23. PubMed ID: 12544300
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Ultrasensitive detection of prostate specific antigen in the followup of 422 patients after radical prostatectomy.
    Haese A, Huland E, Graefen M, Hammerer P, Noldus J, Huland H.
    J Urol; 1999 Apr 01; 161(4):1206-11. PubMed ID: 10081870
    [Abstract] [Full Text] [Related]

  • 17. [Salvage radiotherapy for patients with PSA relapse after radical prostatectomy: comparisons among ASTRO and Phoenix biochemical failure definitions].
    Quero L, Mongiat-Artus P, Ravery V, Hennequin V, Maylin C, Desgrandchamps F, Hennequin C.
    Cancer Radiother; 2009 Jul 01; 13(4):267-75. PubMed ID: 19446487
    [Abstract] [Full Text] [Related]

  • 18. Usefulness of the nadir value of serum prostate-specific antigen measured by an ultrasensitive assay as a predictor of biochemical recurrence after radical prostatectomy for clinically localized prostate cancer.
    Sakai I, Harada K, Kurahashi T, Muramaki M, Yamanaka K, Hara I, Inoue TA, Miyake H.
    Urol Int; 2006 Jul 01; 76(3):227-31. PubMed ID: 16601384
    [Abstract] [Full Text] [Related]

  • 19. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L, Jones TD, Lin H, Eble JN, Zeng G, Carr MD, Koch MO.
    J Urol; 2005 Dec 01; 174(6):2181-5. PubMed ID: 16280760
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.